Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature.
Fourteen cases of gynecomastia occurring during highly active antiretroviral therapy (HAART) have been reported in the literature. To date, no specific therapeutic approach has been proposed, and gynecomastia has usually persisted. We report 4 new cases of HAART-induced gynecomastia that were successfully treated with percutaneous dihydrotestosterone gel.
Benveniste
O
O
Service de Médecine Interne, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. olivier.benveniste@psl.ap-hop-paris.fr
Simon
A
A
Herson
S
S
D000287:Administration, Topical; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D013196:Dihydrotestosterone / Q000008:administration & dosage*; D005782:Gels; D006177:Gynecomastia / Q000139:chemically induced* / Q000188:drug therapy*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008297:Male
D005782:Gels; D013196:Dihydrotestosterone